CoChat

Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes

Hero, Christel, Rawshani, Araz, Svensson, Ann-Marie, Franzén, Stefan, Eliasson, Björn, Eeg-Olofsson, Katarina, Gudbjörnsdottir, Soffia · 2016 · Diabetes Care

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the effect of lipid-lowering therapy (LLT) in primary prevention on cardiovascular disease (CVD) and death in type 1 diabetes. RESEARCH DESIGN AND METHODS: We used the Swedish National Diabetes Register (NDR) to perform a propensity score–based study. Propensity scores for treatment with LLT were calculated from 32 baseline clinical and socioeconomic variables. The propensity score was used to estimate the effect of LLT in the overall cohort (by stratification). We estimated risk of acute myocardial infarction, stroke, coronary heart disease, and cardiovascular and all-cause mortality in individuals with and without LLT using Cox regression. A total of 24,230 individuals included in 2006–2008 NDR with type 1 diabetes without a history of CVD were followed until 31 December 2012; 18,843 were untreated and 5,387 treated with LLT (97% statins). The mean follow-up was 6.0 years. RESULTS: The propensity score allowed balancing of all 32 covariates, with no differences between treated and untreated after accounting for propensity score. Hazard ratios (HRs) for treated versus untreated were as follows: cardiovascular death 0.60 (95% CI 0.50–0.72), all-cause death 0.56 (0.48–0.64), fatal/nonfatal stroke 0.56 (0.46–0.70), fatal/nonfatal acute myocardial infarction 0.78 (0.66–0.92), fatal/nonfatal coronary heart disease 0.85 (0.74–0.97), and fatal/nonfatal CVD 0.77 (0.69–0.87). CONCLUSIONS: This observational study shows that LLT is associated with 22–44% reduction in the risk of CVD and cardiovascular death among individuals with type 1 diabetes without history of CVD and underlines the importance of primary prevention with LLT to reduce cardiovascular risk in type 1 diabetes.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc15-2450

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 80

Metadata

Authors
Hero, C., Rawshani, A., Svensson, A.-M., Franzén, S., Eliasson, B., Eeg-Olofsson, K., & Gudbjörnsdottir, S.
Affiliations
  • Sahlgrenska University Hospital (SE)
  • Swedish National Diabetes Register, Gothenburg, Sweden
  • Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden
Corresponding author
Hero, Christel
Venue
Diabetes Care
Published
2016-04-18
Volume
39
Issue
6
Pages
996-1003
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2337090699
Cited by
78
References
22
Citations by year
2026: 8 · 2025: 11 · 2024: 9 · 2023: 6 · 2022: 8 · 2021: 6 · 2020: 12 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 1
FWCI
6.65
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
lipid-lowering therapy, type 1 diabetes, statins, cardiovascular disease, cardiovascular mortality, all-cause mortality, acute myocardial infarction, stroke, coronary artery disease, primary prevention, cardiovascular risk reduction
MeSH terms
Adult, Cardiovascular Diseases, Cause of Death, Coronary Disease, Diabetes Mellitus, Type 1, Female, Humans, Hyperlipidemias, Male, Middle Aged, Myocardial Infarction, Registries, Risk Factors, Sweden, Proportional Hazards Models, Case-Control Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Young Adult, Propensity Score

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.